Targeting HER2 in Advanced Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Human epidermal growth factor receptor 2 (HER2) is an oncogene amplified in ~20% of breast cancers.
• HER2 amplification is associated with a poorer prognosis without targeted treatment.
• Targeted anti-HER2 therapies have revolutionized treatment for metastatic HER2-positive breast cancer.

Purpose of the Study:

• To review data from completed randomized phase III clinical trials on targeted anti-HER2 therapies.
• To discuss emerging advances addressing unmet needs in metastatic HER2-positive breast cancer.

Main Methods:

• Systematic review of randomized phase III clinical trials.
• Analysis of data on efficacy and safety of anti-HER2 agents.
• Discussion of ongoing and future therapeutic strategies.

Main Results:

• Targeted anti-HER2 therapies are standard of care for first-line and subsequent treatment settings.
• These therapies have dramatically improved disease control and survival rates.
• Evidence from phase III trials supports their efficacy in metastatic HER2-positive breast cancer.

Conclusions:

• Targeted anti-HER2 therapies represent a major advancement in breast cancer treatment.
• Continued research is essential to address remaining challenges and improve patient outcomes.
• Emerging therapies hold promise for further enhancing treatment efficacy.